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Abstract: The outermost barrier layer of the skin is the stratum corneum (SC), which consists
of corneocytes embedded in a lipid matrix. Biosynthesis of barrier lipids occurs de novo in the
epidermis or is performed with externally derived lipids. Hence, in vitro developed human skin
equivalents (HSEs) are developed with culture medium that is supplemented with free fatty acids
(FFAs). Nevertheless, the lipid barrier formation in HSEs remains altered compared to native human
skin (NHS). The aim of this study is to decipher the role of medium supplemented saturated FFA
palmitic acid (PA) on morphogenesis and lipid barrier formation in HSEs. Therefore, HSEs were
developed with 100% (25 µM), 10%, or 1% PA. In HSEs supplemented with reduced PA level, the
early differentiation was delayed and epidermal activation was increased. Nevertheless, a similar SC
lipid composition in all HSEs was detected. Additionally, the lipid organization was comparable for
lamellar and lateral organization, irrespective of PA concentration. As compared to NHS, the level
of monounsaturated lipids was increased and the FFA to ceramide ratio was drastically reduced in
HSEs. This study describes the crucial role of PA in epidermal morphogenesis and elucidates the role
of PA in lipid barrier formation of HSEs.
Keywords: primary cell culture; artificial skin; bioengineering; palmitic acid; free fatty acid; ceramide;
lipid metabolism; mass spectrometry
1. Introduction
The human skin protects the body from desiccation and environmental challenges through the
establishment of a multilayered barrier system. The main physical barrier is formed by the outermost
layer of the epidermis, which is the stratum corneum (SC). This SC consists of corneocytes embedded
in a lipid matrix (Supplementary Figure S1a–c). The lipid matrix forms the only continuous penetration
pathway through the SC. Therefore, it is crucial for the functionality of the barrier.
Sophisticated in vitro tools which resemble native human skin (NHS) to a high extent are
three-dimensional human skin equivalents (HSEs). Therefore, these are widely applied in preclinical
screenings and for research purposes to increase understanding of skin biology and epidermal
barrier formation in healthy and diseased phenotypes [1–6]. HSEs mimic NHS in morphologic
appearance, including the presence of distinguishable epidermal layers and formation of the SC [7–9].
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Characterization of the barrier formation in HSEs revealed similarities as well as differences compared
to the barrier formation of NHS. Similarities in the SC lipid matrix between HSEs and NHS include
the presence of the main lipid classes and subclasses thereof, and the presence of distinctive lipid
lamellae in the intercorneocyte space [7,8,10]. However, differences were reported regarding the lipid
composition, such as an increased level of monounsaturated lipids, a reduced chain length of free
fatty acids (FFAs) and ceramides (CERs), and a different CER subclass profile [10,11]. Changes in lipid
composition coincides with a reduction in the length of the repeat distance of the long periodicity
phase (LPP), as well as a lack in the formation of the short periodicity phase (SPP) (Supplementary
Figure S1d,e) [7,12]. Also, the formation of a predominant hexagonal lateral organization was observed
in HSEs, in contrast to a predominant orthorhombic lateral organization in NHS (Supplementary
Figure S1f) [8]. These compositional and organizational differences directly contribute to an impaired
skin barrier function, as compound penetration occurs at an elevated rate [4,5,7]. Although the altered
composition of CERs in the SC of HSE is relatively well described [7,10,11,13], there is still a need for
more detailed characterization of the composition of FFA in the SC of HSEs.
For the formation of the epidermal barrier, FFAs are essential for numerous processes. Most
prominent are to serve as building blocks for more complex lipids (e.g., CERs) of the lipid barrier
and to contribute to the structure of the lipid matrix [14–16]. FFAs are mainly synthesized de novo
in the skin, although these could also be taken up from the systemic circulation originating from
dietary resources [14,17]. Both are important, since the epidermis can switch between local to systemic
sources for lipid barrier repair [17,18]. To improve the barrier formation in HSEs, it is essential to better
comprehend the in vitro lipid biosynthesis pathways.
To mimic the systemic availability of lipids, the culture medium of HSEs is supplemented with a
mixture of FFAs during submerged and air-exposed phases. This mixture consists of the essential FFA
linoleic acid (LA; C18:2(ω-6)), the conditionally essential FFA arachidonic acid (AA; C20:4(ω-6)), and
the saturated FFA (saFFA) palmitic acid (PA; C16:0). These exogenous FFAs are shown to be taken
up and processed in the epidermis of HSEs to become part of the SC lipid barrier [19–21]. Several
studies have been performed to optimize the timepoint of supplementation, concentration, and ratio
of FFAs during the development of HSEs [19,20,22]. These showed that supplementation with FFAs
was crucial to induce the formation of lamellar bodies [22], although a fourfold increase in either
PA level or in total FFA mixture in the medium during generation of HSEs did not modulate the
FFA composition in SC [19]. However, too high concentrations of supplemented saFFAs could lead
to lipotoxic responses [23,24]. This would result in an elevated stearoyl-CoA desaturase-1 (SCD-1)
expression and a higher level of monounsaturated lipids [25], which are also observed in HSEs [11].
However, LA and AA are not involved in a saFFA-induced lipotoxic response, which is mediated
by increased expression of SCD-1 [26]. Considering this, it is of interest to elucidate the role of
supplementation levels of PA during generation of HSEs.
In this study, we aim to decipher the effect of PA supplementation on the epidermal morphogenesis
and barrier formation of HSEs and to obtain more insights in the presence of FFAs in the SC of HSEs.
To this end, we supplemented the medium with reduced PA concentrations and studied the dermal
and epidermal morphogenesis and lipid barrier formation of full thickness models (FTMs) and NHS.
Herein, we report that the original PA supplementation concentration is most optimal for the formation
of a well-ordered epidermal morphogenesis. Additionally, we observed a considerable reduction
in the absolute amount of FFAs in the SC of FTMs as compared to that of NHS, irrespective of the
PA concentration.
2. Results
2.1. FTMs Generated with Various PA Levels Displayed Similar Epidermal Architecture
FTMs were developed with 100% (FTM100%PA), 10% (FTM10%PA), or 1% (FTM1%PA) of the original
medium PA concentration (25 µM) and were compared to NHS (Figure 1a). This revealed a similar
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appearance in all conditions tested. Quantification of the thickness of the viable epidermis and number
of corneocyte layers revealed an equal epidermal thickness and a similar number of corneocyte layers
in FTMs, irrespective of PA level (Figure 1b,c). As compared to NHS, the FTMs lack the epidermal rete
ridges and have a thicker viable epidermis. The number of corneocyte layers was similar, despite the
lack in exfoliation in FTMs. This indicates that FTMs supplemented with reduced level of PA contain a
well-ordered epidermal architecture.
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Figure 1. Generation of full thickness models (FTMs) supplemented with various palmitic acid (PA) 
levels. (a) Macro and micro anatomy of native human skin (NHS) and indicated FTMs. Histology 
examined after hematoxylin and eosin (HE) staining. Scale bar represents 100 μm. (b) Quantified 
epidermal thickness of NHS and indicated FTMs. (c) Number of corneocyte layers reflects the stratum 
corneum (SC) thickness. Data represents mean + SD, n = 4, *** indicates p < 0.001. 
2.2. Strong Reduction in PA Supplementation Level Compromised the Epidermal Morphogenesis 
Assessments of epidermal and dermal morphogenesis were performed using protein 
biomarkers. The late differentiation program was unaffected by reduction in PA (loricrin, filaggrin, 
involucrin) (Figure 2a). As compared to NHS, involucrin was more expressed in the spinous layer, 
while filaggrin and loricrin were equally localized. Early differentiation, which indicates the 
transition of keratinocytes from the basal cell layer to the spinous cell layer, was delayed in HSEs 
developed with reduced PA levels, most severe at 1% indicated by keratin 10 (K10) and 1 (K1) 
expression. This was confirmed after quantification of the K10 or K1 positive area in the suprabasal 
viable epidermis, which was lowest in FTM1%PA. Lower epidermal layer biomarker K5/8 was 
expressed in two epidermal segments in FTM100%PA, whereas it was diffuse expressed throughout the 
epidermis of FTM10%PA and FTM1%PA. As compared to NHS, expression of the K5/8 proteins is detected 
in more suprabasal epidermal layers. Epidermal activation of the viable epidermis was found to be 
directly affected by PA supplementation levels (Figure 2b). Moderate K16 expression was detected 
in FTM10%PA, whereas strong K16 expression was detected in FTM1%PA. Nevertheless, K17 remained 
absent in all conditions. As compared to NHS, epidermal activation was only present in vitro. 
Another characteristic of epidermal morphogenesis is the proliferation of the viable epidermis. 
Biomarker Ki67 remained expressed only at the basal layer and the proliferation index was 
comparable in all conditions (Figure 2c). The viable epidermis is connected to the dermis via the 
basement membrane, which was generated in vitro in a similar proportion at all exogenous PA levels 
(Figure 2d). As PA is a lipid which could also be bioactive in the dermis [15,27], dermal 
morphogenesis was examined for fibroblast distribution and fibroblasts subpopulations with focus 
on myofibroblasts (Figure 2e). Both were similar regardless of PA levels, although fibroblast 
Figure 1. Generation of full thickness models (FTMs) supplemented with various palmitic acid (PA)
levels. (a) Macro and micro anatomy of native human skin (NHS) and indicated FTMs. Histology
examined after hematoxylin and eosin (HE) staining. Scale bar represents 100 µm. (b) Quantified
epidermal thickness of NHS and indicated FTMs. (c) Number of corneocyte layers reflects the stratum
corneum (SC) thickness. Data represents mean + SD, n = 4, *** indicates p < 0.001.
2.2. Strong Reduction in PA Supplementation Level Compromised the Epidermal Morphogenesis
Assessments of epidermal and dermal morphogenesis were performed using protein biomarkers.
The late differentiation program was unaffected by reduction in PA (loricrin, filaggrin, involucrin)
(Figure 2a). As compared to NHS, involucrin was more expressed in the spinous layer, while filaggrin
and loricrin were equally localized. Early differentiation, which indicates the transition of keratinocytes
from the basal cell layer to the spinous cell layer, was delayed in HSEs developed with reduced PA
levels, most severe at 1% indicated by keratin 10 (K10) and 1 (K1) expression. This was confirmed after
quantification of the K10 or K1 positive area in the suprabasal viable epidermis, which was lowest
in FTM1%PA. Lower epidermal layer biomarker K5/8 was expressed in two epidermal segments in
FTM100%PA, whereas it was diffuse expressed throughout the epidermis of FTM10%PA and FTM1%PA.
As compared to NHS, expression of the K5/8 proteins is detected in more suprabasal epidermal layers.
Epidermal activation of the viable epidermis was found to be directly affected by PA supplementation
levels (Figure 2b). Moderate K16 expression was detected in FTM10%PA, whereas strong K16 expression
was detected in FTM1%PA. Nevertheless, K17 remained absent in all conditions. As compared to NHS,
epidermal activation was only present in vitro. Another characteristic of epidermal morphogenesis
is the proliferation of the viable epidermis. Biomarker Ki67 remained expressed only at the basal
layer and the proliferation index was comparable in all conditions (Figure 2c). The viable epidermis
is connected to the dermis via the basement membrane, which was generated in vitro in a similar
proportion at all exogenous PA levels (Figure 2d). As PA is a lipid which could also be bioactive in
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the dermis [15,27], dermal morphogenesis was examined for fibroblast distribution and fibroblasts
subpopulations with focus on myofibroblasts (Figure 2e). Both were similar regardless of PA levels,
although fibroblast distribution in FTMs was more continuous and not divided in a papillary and
reticular dermal zone as observed in NHS.
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2.3. Supplementation of FTMs with Various PA Levels Resulted in an Equal Composition of FFA in the SC  
We then evaluated the lipid barrier formation in the FTMs by examination of the SC lipid 
composition. A similar amount of extracted lipids was observed in all FTMs, which was higher in 
NHS (Figure 3a). The composition of FFAs was determined using the liquid chromatography-mass 
spectrometry (LC-MS) FFA analysis (Supplementary Figure S2a). The absolute amount of FFAs 
remained similar despite the reduction in supplemented PA (Figure 3b). As compared to NHS, a 
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Figure 2. Morphogenesis of FTMs supplemented with different PA levels. Expression of protein
biomarkers in NHS and FTMs of (a) late and terminal differentiation (loricrin, filaggrin, and involucrin),
early differentiation (keratin 10 and 1), and basal layer (keratin 5/8). The percentage of K10 and K1
positive area in the suprabasal epidermis is provided (mean ± SD, n = 4). (b) Epidermal activation
(keratin 16 and keratin 17), (c) proliferation (Ki67) with i dicated proliferatio index (mean ± SD, n = 4),
(d) dermal–epidermal ju ction (collagen type IV and laminin 332), (e) fibroblasts distribution (vimentin),
and fibroblasts stress signaling (alpha smooth muscle actin) biomarker protein expression. Nuclei
are counterstained blue using hematoxylin or DAPI, yellow dotted line indicates dermal–epidermal
junction. Scale bar indicates 100 µm.
2.3. Supplementation of FTMs with Various PA Levels Resul ed in an Equal Compositi n of FFA in the SC
We then evaluated the lipid barrier formation in the FTMs by examination of the SC lipid
composition. A similar amount of extracted lipids was observed in all FTMs, which was higher in
NHS (Figure 3a). The composition of FFAs was determined using the liquid chromatography-mass
spectrometry (LC-MS) FFA analysis (Supplem ntary Figure S2a). The absolute amount of FFAs
remained similar despite the reduction in supplemented PA (Figure 3b). As compared to NHS,
a substantial reduction in level of FFAs was observed. The reduction in absolute amount of FFAs is
mainly ascribed to the reduced presence of saFFAs with a carbon (C) chain length ≥ C23:0 (Figure 3c).
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The absolute amount of short chain monounsaturated FFA (muFFA) C16:1 and C18:1 was similar in
FTMs and NHS, whereas the long chain muFFAs ≥ C22:1 were more abundant in FTMs (Figure 3d).
The polyunsaturated FFA (puFFA) C18:2 was substantially reduced in FTMs as compared to NHS
(Figure 3e).
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Figure 3. Free fatty acid (FFA) composition in the SC o HS and in FTM supplement d with different
PA levels. (a) Extracted lipids were plotted per mg SC of NHS and the FTMs supplemented with
100%, 10%, or 1% PA. (b) Absolute amount of FFAs in the SC of NHS and of indicated FTMs. (c) Bar
diagram of the saturated FFA (saFFA) profile as presented in absolute amount. (d) Bar diagram of the
monounsaturated FFA (muFFA) profile as presented as absolute amount. (e) Bar diagram of the puFFA
C18:2 per mg SC. (f) Relative amount of saFFAs in the SC of NHS and FTMs. (g) Relative amount of
muFFAs in the SC of NHS and FTMs. (h) The level of muFFAs as percentage of total FFAs. All data for
NHS, FTM100%PA, FTM10%PA, and FTM1%PA. (i) Bar diagram of the MCL of total FFAs. Data represents
mean + SD, n = 3. LOQ indicates below limit of quantification. Significance indicated by * p < 0.05,
** p < 0.01, *** p < 0.001.
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The absolute quantities were used to calculate the relative amount of FFAs. No difference in
the relative saFFA and muFFA composition was observed between the FTM100%PA, FTM10%PA, and
FTM1%PA. When comparing the FTMs with NHS, differences in saFFA and muFFA composition were
observed (Figure 3f,g). In contrast to NHS, in the SC of FTMs there was a higher relative level of FFA
C20:0 and C22:0, which was counterbalanced by a reduced relative abundance of FFA with chain
length ≥ C25:0. The FFA C24:0 remained the most abundant FFA in the SC of both FTMs and of NHS.
Regarding the relative abundance of muFFAs, in the SC of FTMs there was a higher level of C20:1,
C22:1, and C24:1, which reduced the relative abundance of C18:1, in agreement with the observations
of the absolute level of muFFAs (Figure 3g).
The differences between the FFA composition of NHS and FTMs were also reflected in the level of
muFFAs and in the MCL of FFAs. A considerable increase in muFFA content in the SC was detected in
FTMs as compared to NHS (Figure 3h). In addition, the mean carbon chain length (MCL) of the total
FFAs was reduced in FTMs as compared to NHS (Figure 3i).
Our quantified LC-MS FFA analysis did not include FFA C16:0 and C18:0 due to manufacturer’s
contamination of C16:0 and C18:0 in the solvents, and it excluded very long chain muFFAs C26:1 and
C28:1 due to the absence of these FFA standards. To still provide an indication on the presence of
these FFAs, we analyzed the area under curve (AUC) of the FFAs and corrected these for the internal
standard (ISTD) and contamination, followed by plotting the relative amount. First, we observed
FFA C16:0 at a similar and C18:0 at a higher level in the FTMs as compared to NHS (Supplementary
Figure S3a). Second, we observed that the muFFAs C26:1 and C28:1 are present at higher fractions
in the SC of FTMs as compared to that of NHS (Supplementary Figure S3b), in line with previous
observations [11]. This indicates that there are more short chain FFAs present in FTMs and it implies
that the level of muFFAs calculated with the quantified FFA data is underestimating the fraction of
muFFAs in the SC of FTMs.
These results indicate that variations in supplemented PA lead to a similar FFA composition, and
that there are substantial differences between the FFA profiles of NHS and FTMs.
2.4. Variations in Supplemented PA did not alter the Composition of CERs in the SC
As FFAs serve as building blocks for more complex lipids (i.e., CERs), we assessed whether
reduction in PA could affect the CER composition. The CER lipidomic analysis revealed the presence
of all major subclasses in NHS and the FTMs on the LC-MS ion maps (Supplementary Figure S2b). In
FTMs, an increased presence of CERs with a mass lower than 600 atomic mass units (amu) was detected,
which is a premature indication for an altered CER composition. The CER data was quantified to
absolute amounts per mg of SC. This revealed a similar absolute amount of CERs in all FTMs, although
the level of CER per mg of SC in NHS was significantly lower (Figure 4a). Since the absolute amount of
FFA per mg of SC was also calculated (Figure 3b), this provided the opportunity to calculate the ratio
between FFAs and CERs at this detailed level. The obtained ratio was drastically reduced in FTMs as
compared to NHS, irrespective of PA level (Figure 4b). Then, the composition of the CER subclasses
was evaluated by comparing the distribution profile of CER[non-EO] versus CER[EO], which revealed
a high level of similarity in all FTMs and NHS (Figure 4c).
Next, the absolute amount of each CER subclass was determined for FTM100%PA, FTM10%PA,
FTM1%PA, and NHS (Figure 4d). The data for CER[non-EO] represents the saturated CER (saCER)
and the monounsaturated CER (muCER). The bars of CER[EO] subclasses represent a combination
of 4 different subgroups, which are muCER[EO-18:2], saCER[EO-18:2] + muCER[EO-18:1], and
saCER[EO-18:1]. The CER subclass profiles of FTMs generated with different PA levels showed a high
level of similarity. Considerable differences were observed comparing the subclass profiles of NHS
and FTMs, which included an increased quantity of CER[NS], CER [AS], CER [AH], and most of the
CER[EO] subclasses. This resulted in a relative abundance of the CER subclasses with a strong reduced
fraction of CER [NP], while most other CER subclasses changed in abundancy, but to a lesser extent
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(Figure 4e). The data strongly indicate that biosynthesis pathways generating CER subclasses [NS],
[AS], and [EOS] are most altered in vitro, whereas this is not influenced by PA supplementation.
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 7 of 18 
 
diagram of the saturated FFA (saFFA) profile as presented in absolute amount. (d) Bar diagram of the 
monounsaturated FFA (muFFA) profile as presented as absolute amount. (e) Bar diagram of the 
puFFA C18:2 per mg SC. (f) Relative amount of saFFAs in the SC of NHS and FTMs. (g) Relative 
amount of muFFAs in the SC of NHS and FTMs. (h) The level of muFFAs as percentage of total FFAs. 
All data for NHS, FTM100%PA, FTM10%PA, and FTM1%PA. (i) Bar diagram of the MCL of total FFAs. Data 
represents mean + SD, n = 3. LOQ indicates below limit of quantification. Significance indicated by * 
p < 0.05, ** p < 0.01, *** p < 0.001. 
 
Figure 4. Ceramide (CER) composition in the SC of NHS and in FTM supplemented with different 
PA levels. (a) Absolute amount of CERs in the SC of NHS and of FTMs. (b) Ratio of FFAs and CERs 
present in the SC. (c) Distribution profile of total CER[non-EO] and CER[EO] in the SC presented as 
relative amount. (d) Absolute subclass profile of CERs plotted as nmol per mg of SC. (e) Subclass 
profile of CERs plotted as relative amount per CER subclass in percentage of the total CER quantity. 
(f) The MCL of the CER[non-EO] subclasses. (g) The MCL of the CER[EO] subclasses. (h) The level of 
muCER in the CER[non-EO] subclasses, presented of total CER[non-EO]. All data for NHS, FTM100%PA, 
Figure 4. Ceramide (CER) composition in the SC of NHS and in FT lemented with different PA
levels. (a) Absolute mount of CERs in the SC of NHS and of FTMs. (b) Ratio of FFAs and CERs present
in the SC. (c) Distribution profile of total CER[non-EO] and CER[EO] in the SC presented as relative
amount. (d) Absolute subclass profile of CERs plotted as nmol per mg of SC. (e) Subclass profile of
CERs plotted as relative amount per CER subclass in percentage of the total CER quantity. (f) The MCL
of the CER[non-EO] subclasses. (g) The MCL of the CER[EO] subclasses. (h) The level of muCER in the
CER[non-EO] subclasses, presented of total CER[non-EO]. All data for NHS, FTM100%PA, FTM10%PA,
and FTM1%PA represents mean + SD, n = 3. Significance indicated by * p < 0.05, ** p < 0.01, *** p < 0.001.
The CER[EO] subclasses are composed of four different subgroups, as shown in Supplementary
Figure S4. In FTMs, no differences were observed upon reduced PA supplementation in the CER[EO]
subgroups. Comparing FTMs to NHS, a difference for the CER[EO] subgroups is the presence of
saCER[EO-18:1] in contrast to its absence in NHS.
Subsequently, we addressed the MCL of CER[non-EO] and CER[EO] (Figure 4f,g). The MCL of
CER[non-EO] in NHS was higher than that of FTMs, but no differences were observed regarding PA
levels. Figure 4g shows a similar MCL of CER[EO] in NHS and FTMs with different PA conditions.
The carbon chain length distributions for the CER[non-EO] and CER[EO] deviated significantly from
that of NHS, but were similar for the various levels of PA (Supplementary Figure S5). Importantly, the
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increased presence of C34, C36, C38, C40, and C42 CER[non-EO] in both absolute and relative level in
FTMs as compared to NHS is a major difference.
As a final point, the level of muCERs was calculated as percentage of the total CERs (Figure 4h). The
level of muCER[non-EO] in the SC of FTMs was not influenced after reduction of the PA concentration,
although this was considerably increased in FTMs as compared to NHS.
2.5. FTMs Supplemented with Reduced PA Exhibited a Similar Lipid Organization
After addressing the lipid composition, the barrier formation was examined for lamellar
organization by small angle X-ray diffraction (SAXD) and for lateral organization by Fourier transform
infrared spectroscopy (FTIR). The obtained SAXD diffraction profiles were indicative for the presence
of the long periodicity phase (LPP) in FTMs (Figure 5a). The repeat distance of the LPP was determined
based on indicated order of diffraction peaks, which revealed a high similarity between FTM100%PA,
FTM10%PA, and FTM1%PA (Figure 5b). The repeat distance of the LPP in FTMs was considerably
reduced as compared to that of NHS [28]. For the lateral organization, the FTIR spectrum at the
methylene rocking vibration region is indicative for the orthorhombic lateral packing when there
were two peaks present, whereas the hexagonal lateral packing is indicated by a single peak [7]. In
FTM100%PA, FTM10%PA, and FTM1%PA the hexagonal lateral packing was observed (Figure 5c). In
contrast, the lipids were predominantly arranged in the orthorhombic lateral packing in NHS. Between
30 ◦C and 40 ◦C, the intensity of the peak at 730 cm−1 reduced in the FTIR spectrum of NHS, indicating
a transition from orthorhombic to hexagonal packing.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 9 of 18 
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2.6. Reduction of Supplemented PA Resulted in a Similar Expression of Lipid Processing Enzymes 
To obtain more information on the lipid biosynthesis pathway in FTMs, we assessed the 
expression of various lipid processing enzymes related to the barrier formation in the SC. The 
enzymes SCD-1, ELOVL6, CERS5, and CERS6 are able to process PA by desaturation to form C16:1, 
elongation to produce C18:0, or synthesis of CERs with a C16 acyl-chain, respectively [29–31]. The 
level of gene expression for these enzymes was similar in FTM100%PA, FTM10%PA, and FTM1%PA (Figure 
6a). Also, expression of ELOVL1 and ELOVL4 remained similar. Furthermore, gene expression of 
lipogenic mediators (i.e., SREBP-1c, FAS, ACC) remained unaffected (Figure 6b). Lipid storage 
pathways were unaffected in all conditions tested based on the similar expression of enzymes 
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Figure 5. Lipid matrix organization in FTMs supplemented with different PA levels. (a) Small angle
X-ray diffraction (SAXD) profiles of FTMs plotted as intensity in arbitrary units (a.u.) over the scattering
vector q. The orders of diffraction (I, II, and III) are indicated by dashed lines, phase separated
cholesterol is indicated by the asterisk (*) symbol. Unknown phases are indicated by the number sign
(#). (b) Bar plot showing the repeat distance of the LPP i NHS and FTMs based on the indicated orders
of diffraction. Data f r NHS was obtained from Bouwstra et al. [28], data r presents me n + SD, n = 3.
(c) Fourier transform infrared spectroscopy (FTIR) spectra pl tted as absorbance v r the wavenumber
in the methylene rocking vibrational region. On the right y-axis the temperature is shown at which
the measurement occurred. Representative FTIR spectra were plotted for NHS and for FTMs with
indicated level of supplemented PA.
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2.6. Reduction of Supplemented PA Resulted in a Similar Expression of Lipid Processing Enzymes
To obtain more information on the lipid biosynthesis pathway in FTMs, we assessed the expression
of various lipid processing enzymes related to the barrier formation in the SC. The enzymes SCD-1,
ELOVL6, CERS5, and CERS6 are able to process PA by desaturation to form C16:1, elongation to
produce C18:0, or synthesis of CERs with a C16 acyl-chain, respectively [29–31]. The level of gene
expression for these enzymes was similar in FTM100%PA, FTM10%PA, and FTM1%PA (Figure 6a). Also,
expression of ELOVL1 and ELOVL4 remained similar. Furthermore, gene expression of lipogenic
mediators (i.e., SREBP-1c, FAS, ACC) remained unaffected (Figure 6b). Lipid storage pathways were
unaffected in all conditions tested based on the similar expression of enzymes involved in mono-, di-,
and triglyceride synthesis (i.e., MGAT, DGAT2, GPAT) and biosynthesis of cholesterol esters (ACAT)
(Figure 6c). Additionally, there was no evidence of a change in the amount of diglycerides based on
the LC-MS CER ion maps. On protein level, the expression of lipid processing enzymes SCD-1 and
ELOVL6 was similar irrespective of PA level supplemented into the medium (Figure 6d). As compared
to NHS, the expression of SCD-1 was upregulated in FTMs, whereas the expression of ELOVL6 was
similar. Together, these results show that lipid biosynthesis in FTMs remained similar after reduction
of supplemented PA.
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Figure 6. Lipid processing enzyme expression in FTMs supplemented with different PA levels. (a) Gene
expression of direct and indirect PA processing enzymes SCD-1, ELOVL1, ELOVL4, ELOVL6, CERS5,
and CERS6 in FTMs supplemented with indicated PA levels. (b) Gene expression of lipogenic mediators
SREBP-1c, FAS, and ACC in FTMs. (c) Gene expression of lipid storage enzymes MGAT, DGAT2, GPAT,
and ACAT in FTMs. Data represents mean ± SD, n = 4. (d) Protein expression of PA processing enzymes
SCD-1 and ELOVL6 in NHS and indicated FTMs. Proteins are shown in red and nuclei in blue. Scale
bar represent 50 µm.
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3. Discussion
In this study, we showed that addition of the bioactive lipid PA to the culture medium of HSEs
supports a well-orchestrated epidermal morphogenesis. Irrespective of PA level in the culture medium,
the SC lipid barrier composition and organization were similar. This indicates that the original level
of PA was adequate and that the aberrant lipid barrier formation in HSEs is not associated with the
overabundance of this saFFA in the culture medium. Furthermore, we showed that the level of FFAs
in the SC of FTMs is substantially reduced as compared to NHS, which emerged as target for future
optimization approaches.
Supplementation of a mixture of essential and non-essential lipids to cultured skin substitutes was
for the first time implemented by Boyce and Williams [22], who showed that it induced the formation
of lamellar bodies and presence of acyl-glucosylceramides to mimic the lipid processing of NHS more
closely. Importantly, the medium supplemented FFAs were found to be processed by the epidermis
and incorporated into the SC of HSEs [19,32]. Histological assessment revealed similar appearance of
the FTMs with varying levels of PA, consistent with results by Spiekstra et al. [33]. However, in the
present study we showed that PA has a direct and pronounced effect on epidermal morphogenesis
by promoting the proper execution of the early differentiation program and reducing the epidermal
activation process. Especially the latter is considered important for a proper barrier formation, as HSEs
which display an activated phenotype generally contain a reduced barrier function [7,10]. In line with
these observations, in vivo data also suggests that an activated epidermis is associated with a reduced
formation and function of the human skin barrier [34,35].
Although epidermal morphogenesis clearly benefits from a sufficient amount of supplemented
PA, the gene and/or protein expression of lipid processing enzymes (i.e., elongases, desaturases, or
ceramide synthases) was not affected by ten to hundredfold reduction of PA. Furthermore, we obtained
insufficient evidence that lipogenic pathways (mediated by SREBP-1c, FAS, and ACC) and lipid storage
pathways (mediated by MGAT, DGAT2, GPAT, and ACAT) were altered after reduced supplementation
of PA. Therefore, it remains of interest to obtain mechanistic insight in the metabolism of external
derived FFAs and in de novo lipid biosynthesis of FFAs in the skin. For instance, PA can be processed
into ceramides, diacylglycerols, triacylglycerols, or saturated glycolipids (i.e., lyso-phosphatidic
acids, lysophosphatidylethanolamine, and phosphatidic acids), although how this affects the SC lipid
composition remains to be identified [36]. Otherwise, PA can be utilized for palmitoylation of skin
specific proteins, which affect the differentiation and cornification within the epidermis [37].
Other attempts to modulate the in vitro biosynthesis of barrier lipids by changing supplementation
of FFAs were performed by Thakoersing et al. [19]. In the absence of PA, no consistent epidermal
architecture was observed, while after a fourfold increase in PA supplementation in epidermal models,
no strong differences were observed in the composition of barrier lipids. These results suggest that
biosynthesis of barrier lipids is difficult to fine-tune by external supplementation of PA, although
a basal supplementation level is crucial to support the proper development of FTMs. Reasonably,
the dynamic de novo lipid biosynthesis plays a dominant role in this, although determination of the
interactions between de novo synthesis and uptake of lipids in vitro remains highly complex due to
the dynamic nature of these intertwined processes [38–42]. Alternatively, addition of other classes of
bioactive lipids besides FFAs (i.e., phytosphingosine) in the culture medium is a promising approach
to improve the SC ceramide subclass profile [43,44].
The altered composition of the major lipids in the SC of HSEs highly contributed to the formation
of the aberrant lipid organization, which are in line with previous reports [7,11]. The reduced repeat
distance of the LPP could be ascribed to a disbalance in the CER subclass profile in combination with
the reduced MCL of both FFAs and CERs [45]. The absence of the SPP is also ascribed to the increased
presence of the CER[EO] subclasses, which play a crucial role in the formation of the LPP [46,47]. The
lateral organization in HSEs is hexagonal, which is caused by the increased presence of muFFAs and
muCERs, the drastic reduction in ratio of FFAs to CERs, and the reduced MCL of both FFAs and CERs,
as revealed by lipid membrane models [48,49]. Importantly, these alterations in lipid organization are
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associated with reduced barrier functionality, which has been confirmed by inside-out and outside-in
evaluations [7,10].
Based on the combination of the LC-MS FFA with the LC-MS CER analysis, we were able to
calculate the ratio of FFA to CER in the SC of NHS and FTMs. Limiting factor in the FFA analysis
was the contamination of the solvents, which forced the exclusion of C16:0 and C18:0. However, after
correcting for the impurities, it was indicated that the short chain C18:0 is relatively more present in
FTMs than in NHS. Furthermore, the C26:1 and C28:1 were excluded due to a lack of corresponding
FFA standards for quantification. However, our results indicate that these muFFAs are more present in
FTMs than in NHS. These factors partially contributed to the reduced abundance of FFAs in FTMs.
Nonetheless, the absolute quantity as well as the FFA profile in the SC of FTMs emerged as highly
interesting and crucial targets for future studies.
Due to the high resolution of our LC-MS CER analysis, increased presence of saCER[EO-18:1] was
monitored in the FTMs, which are not present in NHS [50]. The incorporation of oleic acid (C18:1)
instead of LA (C18:2) could be a result of reduced availability of the essential FFA C18:2, reduced release
from triglycerides, or an excessive rapidity of biosynthesis of CER[EO] during in vitro biosynthesis [20].
Vičanová et al. [20] reported that the addition of 30 µg/mL LA resulted in normalization of the LA
content of the SC barrier. Optimization of the concentration of LA in our culture system (8.42 µg/mL)
is therefore an interesting strategy to reduce the content of saCER[EO-18:1] and increase the level
of saCER[EO-18:2] and the level of puFFA C18:2. On the other hand, LA is a potent ligand for the
peroxisome proliferator-activated receptor alpha [51]. Activation of this nuclear receptor induced
a substantial increase in the presence of CERs in a skin equivalent model [52]. As this potentially
further reduces the FFA to CER ratio, this could be unbeneficial for the lipid composition, organization
and barrier functionality. Alternatively, kinetic studies of the essential FFAs added to keratinocyte
cultures show that the conversion of LA to AA is extremely rapid [53], emphasizing the dynamic FFA
metabolism in keratinocytes and complexity of correcting this in vitro.
With this study, we showed that supplementation with adequate levels of PA during in vitro
HSE reconstruction promotes the generation of a correct epidermal morphology, although the lipid
barrier formation is similar after a ten to hundredfold reduction in external PA levels, although the
lipid barrier formation is similar after a ten to hundredfold reduction in external PA levels. Moreover,
there is a substantial reduction in the quantitative presence of FFAs in the SC of HSEs. These findings
broaden our understanding on the mechanisms underlying in vitro epidermal morphogenesis and
barrier formation and indicate new strategies to better mimic the native skin tissue by HSEs.
4. Materials and Methods
4.1. Generation of FTMs
Surplus female breast skin tissues were obtained after mamma reduction surgeries according to
declaration of Helsinki principles and are regarded in this study as NHS. As reported previously [54],
experiments were conducted in accordance with the Dutch law on medical treatment agreement article
7:467 and in accordance with the code for proper use of human tissue of the Dutch federation of
biomedical scientific societies. As a consequence of this legislation, it is allowed to use anonymized
skin when no objection was made by the well-informed healthy donor.
Epidermis and dermis were separated after removal of adipose tissue followed by enzymatic
digestion and primary cell suspensions were obtained and cultured as described before [3,55]. Isolated
primary keratinocytes and fibroblasts were tested for mycoplasma contamination using polymerase
chain reaction (PCR) analysis before further use. Generation of full thickness models occurred as
described before [10]. In short, a dermis was formed by a collagen lattice harboring 1.2 × 105 primary
fibroblasts. An epidermis was generated on top of the collagen lattice by seeding 2.5 × 105 primary
keratinocytes, which self-organized to form structured epidermal layers after air-exposure. Except for
the PA content, this was reduced to 10% and 1% of the original 100% level (25 µM). FFA mixtures were
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coupled to the carrier molecule bovine serum albumin before supplementation to the medium. FTMs
were grown for 14 days at the air-liquid interface in a cell culture incubator (Memmert, Schwabach,
Germany) at 37 ◦C, 90% RH, 7.3% CO2, and atmospheric oxygen levels. HSE batches were generated
from four different primary cell donors.
4.2. Immunohistochemical Analyses
Sections of NHS, FTM100%, FTM10%, and FTM1% were 24 h fixated in 4% formaldehyde
before rehydration and paraffin embedding or snap frozen for cryopreservation. HE staining was
performed according to methods provided by the manufacturer (VWR, Breda, The Netherlands).
Immunohistochemistry or indirect immunofluorescence was performed on 5 µm sliced formalin fixed
paraffin embedded (FFPE) sections. After deparaffinization and rehydration, heat mediated antigen
retrieval in citrate buffer (pH 6) was performed. Antigen retrieval for collagen type IV staining was
mediated by protease incubation. Next, non-specific antibody binding was reduced by incubation with
normal human serum (Sanquin, Leiden, The Netherlands) prior to application of primary antibodies
(Table S1). Stainings were performed using the streptavidin–biotin–peroxidase system (GE Healthcare,
Buckinghamshire, United Kingdom) according to the manufacturer’s instructions or using indirect
immunofluorescence, as described before [10]. Visualization of the sections occurred using a Zeiss
Axioplan 2 light microscope (Carl Zeiss BV, Breda, The Netherlands) or a Leica CTR5000 fluorescence
microscope (Leica, Wetzlar, Germany). Neither non-specific nor background staining of secondary
antibodies were detected (Supplementary Figure S6a). The number of corneocyte layers in the SC was
determined by safranin red staining and potassium hydroxide expansion as described before [10,56]
(Supplementary Figure S6b). Estimations of the epidermal thickness and proliferation index were
performed as reported earlier [10]. Quantification of K1 and K10 positive area occurred using ImageJ
software (National Institutes of Health, Bethesda, Maryland, USA). The areas were measured using an
in-house developed macro. The non-stained protein areas (no K1 or K10 present) minus the basal layer
area was divided with the total epidermis area and was subtracted from 100%.
4.3. Gene Expression Analyses
Total RNA was extracted from the viable epidermis of FTMs or epidermis and partially attached
dermis of NHS using the Favorprep tissue total RNA mini kit (Favorgen, Ping-Tung, Taiwan). Methods
provided by the manufacturer were followed, with a single exception of an additional 15 min DNA
digestion step after loading the RNA, by means of a RNAse-free DNAse set (Qiagen, Hilden, Germany).
After elution, the RNA concentration was determined using a Nanodrop™ UV-VIS spectrophotometer
(Thermofisher, Waltham, MA, USA). Synthesis of complementary DNA and performance of quantitative
real-time polymerase chain reactions occurred consistently with methods as described before [57].
Details on primer sequences are provided as Table S2.
4.4. Lipidomics Analyses
4.4.1. Lipid Extraction
The stratum corneum was isolated using trypsin digestion and was stored until use in an inert
environment as described before [58]. The lipid extraction was performed using an adapted Bligh and
Dyer extraction procedure as reported by Boiten et al. [13]. After extraction, samples were stored under
argon gas at 4 ◦C until FFA and CER analyses were performed. Dry weight of SC was determined
before and after lipid extraction using a microbalance.
4.4.2. FFA Analysis
Compositional analysis by LC-MS FFA analysis occurred as described before [58]. In short, 2 µL
of 0.75 mg/mL lipid extract was injected into a Waters Acquity UPLC H-class system (Waters, Milford,
MA, USA) for lipid separation using a Purospher Star LiChroCART reverse phase column with 3 µm
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particle size and 55 × 2 mm i.d. (Merck, Darmstadt, Germany). Detection occurred by a XEVO TQ-S
mass spectrometer (Waters) measuring in negative ion mode between m/z 200 and 550 amu. Data
analysis was performed using Masslynx software. Several FFA entities were selected for analysis,
including saFFAs (C20:0, C22:0, C24:0, C26:0, C28:0, and C30:0), muFFAs (C16:1, C18:1, C20:1, C22:1,
and C24:1), and puFFA (C18:2). Quantification occurred using the AUC by correction for the ISTD
deuterated C24 (Cambridge Isotope Laboratories, Andover, MA, USA) and for response using the
calibration curves of the FFA standards (C16:1, C18:1, C18:2, C20:0, C20:1, C22:0, C22:1, C24:0, C24:1,
C26:0, C28:0, and C30:0) (Sigma-Aldrich, St. Louis, MO, USA). Due to manufacturer’s contamination
of C16:0 and C18:0 in the solvents and the lack of available long chain muFFA standards, no additional
FFAs were quantified.
4.4.3. CER Analysis
The extracted samples were evaporated under a stream of nitrogen at 40 ◦C and reconstituted
in 95:2 12 :2
1
2 (v/v/v) heptane:chloroform:methanol to a concentration of 0.3 mg/mL. After addition of
the ISTD N(24deuterated)S(18) (Evonik Industries, Essen, Germany), 5 µL of the sample was injected
into the UPLC-MS setup. This consisted of an Acquity UPLC H-class coupled to an XEVO TQ-S
mass spectrometer (Waters) with an atmospheric pressure chemical ionization chamber. Detection
occurred in positive ion mode measuring full scan m/z between 350 and 1200 amu. Separation of
CERs was performed on a PVA-Sil column with 5 µm particles size and 100 × 2.1 mm i.d. (YMC,
Kyoto, Japan) as described in detail before [13]. Data analysis was performed with Masslynx software.
For the composition analysis, 12 CER subclasses were included with nomenclature as described by
Motta et al. [59] (Figure S1g). For the CER[non-EO], both saturated and monounsaturated classes were
included of: [NdS], [NS], [NP], [NH], [AdS], [AS], [AP], and [AH]. For the CER[EO], both saturated and
monounsaturated classes were included of [EOdS], [EOS], [EOP], and [EOH]. In addition, besides the
linoleic acid residue (C18:2) also the oleic acid residue (C18:1) in CER[EO] was included as described
by Helder et al. [60]. Quantification of the AUCs was performed using a three-dimensional response
model according to the processing method described by Boiten et al. [13]. Corrections for the isotope
overlap of the CER entities containing two 13C atoms to those which only contain 12C (resulting in equal
mass) were performed. After the corrections, the data were converted to absolute amount per mg SC.
4.5. Small Angle X-Ray Diffraction
SAXD analyses were performed with isolated SC. Measurements were performed at the European
Synchrotron Radiation Facility at station BM26B as described extensively by Mojumdar et al. [49]. The
scattering intensity I was measured as a function of the scattering vector q. The latter is defined as
q = 4·π· sinθλ , where θ is the scattering angle and where λ is the wavelength. Using the peak position
(qn), the repeat distance was calculated using the equation d = 2n·πqn , where n is the order of diffraction
peak. The length of the repeat unit of the lipid lamellae was determined based on the peak position of
the first, second and third order of diffraction peak.
4.6. Fourier Transform Infrared Spectroscopy
The isolated SC of NHS, FTM100%PA, FTM10%PA, and FTM1%PA were hydrated during 24 h before
placement between two AgBr cells. FTIR signals were acquired on a Varian 670-IR spectrometer
(Agilent Technologies, Santa Clara, CA, USA) equipped with a broad-band mercury cadmium telluride
detector as described before [57]. The spectrometer was cooled with liquid nitrogen and connected
to a temperature regulating device. Data were collected with a frequency range of 400–4000 cm−1.
Spectral parameters were: Speed 25 kHz, under sampling ratio 2, filter 6.4, and aperture 1 cm−1. Data
acquisition occurred in a time resolution of 240 sec and a length of run equal to 164 min, resulting in a
1 ◦C temperature increase per measurement between 0 ◦C and 40 ◦C. The spectra were analyzed and
deconvoluted with Varian Resolutions Pro software.
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4.7. Statistics
Statistical analyses were performed with GraphPad Prism software (GraphPad Software, La Jolla,
CA, USA). Statistical testing was performed with 1-way or 2-way ANOVA with Holm-Sidak post-test
tests between all FTMs. NHS versus FTM100%PA was tested using unpaired student’s t-test. Significant
differences are presented as * for p < 0.05, ** for p < 0.01, or *** for p < 0.001 with lines between bars for
the former and vertically above NHS for the latter comparison.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/23/
6069/s1. Table S1: Antibodies utilized during immunohistochemical or immunofluorescence analyses. Table S2:
Primer sequences utilized during qPCR analyses. Figure S1: Intercorneocyte lipid matrix of the SC with main
lipid organizations and constituents. Figure S2: LC-MS ion maps of detected FFAs and CERs present in the SC of
NHS and of FTMs generated with 100% PA level as most representative map. Figure S3: Corrected peak areas for
the composition of FFAs. Figure S4. Compositional analysis of CER[EO] subgroups in the SC of FTMs generated
with various PA levels and of NHS. Figure S5. Carbon chain length distribution of CERs in the SC of NHS and of
FTMs generated with varying PA levels. Figure S6: Controls of immunohistochemistry and safranin red staining.
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FFA Free fatty acid
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FTM Full thickness model
HE Hematoxylin and eosin
saFFA Saturated free fatty acid
muFFA Monounsaturated free fatty acid
puFFA Polyunsaturated free fatty acid
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LOQ Limit of quantification
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SAXD Small angle X-ray diffraction
FTIR Fourier transform infrared spectroscopy
ELOVL Elongation of very long chain fatty acids protein
CERS Ceramide synthase
SREBP Sterol regulatory element-binding protein




GPAT Glycerol phosphate acyltransferase
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